The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro
- PMID: 1554239
- DOI: 10.1016/0166-3542(92)90050-f
The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro
Abstract
The combinations of ampligen and zidovudine at ratios of 100:1, 25:1, 10:1, and 1:50 acted synergistically to reduce cytopathology caused by HIV in MT-2 cell cultures. Combination indices were less than 1 at all of these ratios representing different combinations of concentrations and at 3 effective doses (ED30, ED50, ED70). Combination of drugs which show synergism at a wide range of ratios of combinations suggest that they may be useful clinically, and that the antiviral efficacy of ZDV may be increased in combination with ampligen. Synergism was also found between ampligen and zidovudine by reduction of HIV-produced plaques in a HeLa cell line expressing CD-4 receptors. However the combination of ampligen and dideoxyinosine against HIV in MT-2 cells was only additive and not synergistic.
Similar articles
-
Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease.Int J Immunopharmacol. 1991;13 Suppl 1:69-76. doi: 10.1016/0192-0561(91)90127-s. Int J Immunopharmacol. 1991. PMID: 1688087 Clinical Trial.
-
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus.Lancet. 1987 Apr 18;1(8538):890-2. doi: 10.1016/s0140-6736(87)92862-5. Lancet. 1987. PMID: 2882293
-
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.Antimicrob Agents Chemother. 1991 Feb;35(2):322-8. doi: 10.1128/AAC.35.2.322. Antimicrob Agents Chemother. 1991. PMID: 1708977 Free PMC article.
-
[Are immunomodulators capable to improve the activity of nucleoside antiretroviral agents?].Pathol Biol (Paris). 1993 Oct;41(8 Pt 2):794-8. Pathol Biol (Paris). 1993. PMID: 8309723 Review. French.
-
In vitro antiviral activity of didanosine compared with that of other dideoxynucleoside analogs against laboratory strains and clinical isolates of human immunodeficiency virus.Clin Infect Dis. 1993 Feb;16 Suppl 1:S16-21. doi: 10.1093/clinids/16.supplement_1.s16. Clin Infect Dis. 1993. PMID: 8425017 Review.
Cited by
-
Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs. 1993 Sep;46(3):515-578. doi: 10.2165/00003495-199346030-00010. Drugs. 1993. PMID: 7693435 Review.
-
Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.Drugs. 1992 Jul;44(1):94-116. doi: 10.2165/00003495-199244010-00008. Drugs. 1992. PMID: 1379914 Review.
-
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo.J Virol. 1995 Apr;69(4):2557-64. doi: 10.1128/JVI.69.4.2557-2564.1995. J Virol. 1995. PMID: 7884906 Free PMC article.
-
Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection.Eur J Clin Microbiol Infect Dis. 1996 Jul;15(7):580-7. doi: 10.1007/BF01709367. Eur J Clin Microbiol Infect Dis. 1996. PMID: 8874076 Clinical Trial.
-
Estimation of the predictive role of plasma viral load on CD4 decline in HIV-1 subtype C-infected subjects in India.J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):119-25. doi: 10.1097/QAI.0b013e3181911991. J Acquir Immune Defic Syndr. 2009. PMID: 19131898 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials